El proyecto EMECAM: Estudio Multicéntrico Español sobre la Relación entre la Contaminación Atmosférica y la Mortalidad. Antecedentes, participantes, objetivos y métodología.

In recent years, a growing number of studies suggests that increases in air pollution levels may have short-term impact on human health, even at pollution levels similar to or lower than those which have been considered to be safe to date. The different methodological approaches and the varying analysis techniques employed have made it difficult to make a direct comparison among all of the findings, preventing any clear conclusions from being drawn. This has led to multicenter projects such as the APHEA (Short-Term Impact of Air Pollution on Health. A European Approach) within a European Scope. The EMECAM Project falls within the context of the aforesaid multicenter studies and has a wide-ranging projection nationwide within Spain. Fourteen (14) cities throughout Spain were included in this Project (Barcelona, Metropolitan Area of Bilbao, Cartagena, Castellón, Gijón, Huelva, Madrid, Pamplona, Seville, Oviedo, Valencia, Vigo, Vitoria and Saragossa) representing different sociodemographic, climate and environmental situations, adding up to a total of nearly nine million inhabitants. The objective of the EMECAM project is that to asses the short-term impact of air pollution throughout all of the participating cities on the mortality for all causes, on the population and on individuals over age 70, for respiratory and cardiovascular design causes. For this purpose, with an ecological, the time series data analyzed taking the daily deaths, pollutants, temperature data and other factors taken from records kept by public institutions. The period of time throughout which this study was conducted, although not exactly the same for all of the cities involved, runs in all cases from 1990 to 1996. The degree of relationship measured by means of an autoregressive Poisson regression. In the future, the results of each city will be combined by means of a meta-analysis.

Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort.

BACKGROUND Hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, is difficult to diagnose and has limited treatment options with a low survival rate. Aside from a few key risk factors, such as hepatitis, high alcohol consumption, smoking, obesity, and diabetes, there is incomplete etiologic understanding of the disease and little progress in identification of early risk biomarkers. METHODS To address these aspects, an untargeted nuclear magnetic resonance metabolomic approach was applied to pre-diagnostic serum samples obtained from first incident, primary HCC cases (n = 114) and matched controls (n = 222) identified from amongst the participants of a large European prospective cohort. RESULTS A metabolic pattern associated with HCC risk comprised of perturbations in fatty acid oxidation and amino acid, lipid, and carbohydrate metabolism was observed. Sixteen metabolites of either endogenous or exogenous origin were found to be significantly associated with HCC risk. The influence of hepatitis infection and potential liver damage was assessed, and further analyses were made to distinguish patterns of early or later diagnosis. CONCLUSION Our results show clear metabolic alterations from early stages of HCC development with application for better etiologic understanding, prevention, and early detection of this increasingly common cancer.

Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study.

BACKGROUND Left ventricular hypertrophy (LVH) is common in kidney transplant (KT) recipients. LVH is associated with a worse outcome, though m-TOR therapy may help to revert this complication. We therefore conducted a longitudinal study to assess morphological and functional echocardiographic changes after conversion from CNI to m-TOR inhibitor drugs in nondiabetic KT patients who had previously received RAS blockers during the follow-up. METHODS We undertook a 1-year nonrandomized controlled study in 30 non-diabetic KT patients who were converted from calcineurin inhibitor (CNI) to m-TOR therapy. A control group received immunosuppressive therapy based on CNIs. Two echocardiograms were done during the follow-up. RESULTS Nineteen patients were switched to SRL and 11 to EVL. The m-TOR group showed a significant reduction in LVMi after 1 year (from 62 ± 22 to 55 ± 20 g/m2.7; P=0.003, paired t-test). A higher proportion of patients showing LVMi reduction was observed in the m-TOR group (53.3 versus 29.3%, P=0.048) at the study end. In addition, only 56% of the m-TOR patients had LVH at the study end compared to 77% of the control group (P=0.047). A significant change from baseline in deceleration time in early diastole was observed in the m-TOR group compared with the control group (P=0.019). CONCLUSIONS Switching from CNI to m-TOR therapy in non-diabetic KT patients may regress LVH, independently of blood pressure changes and follow-up time. This suggests a direct non-hemodynamic effect of m-TOR drugs on cardiac mass.

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

INTRODUCTION We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). METHODS The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (ΔDAS28) and the European League Against Rheumatism (EULAR) response criteria. RESULTS An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in ΔDAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication. CONCLUSIONS Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA.

Producció i anàlisi estructural d’aliatges magnètics amb memòria de forma

L’objectiu d’aquest projecte és la producció d’aliatges tipus Heusler per estudiar lesestructures corresponents i portar a terme un estudi experimental per poder analitzarla influència de la composició en la transformació martensítica del material, en concret s’avalua la influència de la concentració de Snen presència del Co. Per assolir aquest objectiu es produeixen i es caracteritzen tresaliatges Heusler no estequiomètrics amb composició Mn50Ni45-XSnXCo5 on x pren elvalor de 5, 7’5 i 10. Els aliatges estudiats són. • Mn50Ni40Sn5Co5• Mn50Ni37,5Sn7,5Co5• Mn50Ni35Sn10Co5

The evolution of universities' relations with the business sector in Brazil: What national publications between 1980 and 2012 reveal

ABSTRACT This paper addresses the changes in university-industry relations in Brazil regarding innovation activities. It is based on a survey of articles published in major national journals or presented at the most relevant Brazilian and regional conferences, between 1980 and 2012. The year 1980 was chosen due to the creation of the Technological Innovation Offices (NITs), which was the first government initiative to encourage knowledge transfer from universities to companies; the second was the Innovation Act of 2004. Our assumption was that after the Act the number of academic papers on this subject would increase, bringing new ideas and propositions of models to enhance this relationship. The methodology employed a qualitative, exploratory approach, using bibliographical research and a bibliometric analysis of 247 papers. Literature review of international studies shows the discussion of problems and suggestions for improvements, while in Brazil there is still a debate on whether this collaboration should occur, and if this is a legitimate role for the university. Despite the numerical growth, the content analysis showed few papers on new configurations and procedures for partnership management. We conclude that university-industry relations are not a regular and totally accepted process in Brazilian public universities, which reflect an ideological bias against cooperation with firms.

Circulating insulin-like growth factor-I in pregnancy and maternal risk of breast cancer.

BACKGROUND: Elevated serum concentrations of insulin-like growth factor (IGF)-1 have been associated with increased risk of breast cancer. Previously, we reported a similar association in samples obtained during pregnancy. The current study was conducted to further characterize the association of IGF-1 during pregnancy with maternal breast cancer risk. METHODS: A case-control study was nested within the Finnish Maternity Cohort. The study was limited to primiparous women less than 40 years of age, who donated blood samples during early (median, 12 weeks) pregnancy and delivered a single child at term. Seven hundred and nineteen women with invasive breast cancer were eligible. Two controls (n = 1,434) were matched to each case on age and date at blood donation. Serum IGF-1 concentration was measured using an Immulite 2000 analyzer. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI).RESULTS: No significant associations were observed between serum IGF-1 concentrations and breast cancer risk in both the overall analysis (OR 1.08 (95% CI 0.80-1.47) and in analyses stratified by histological subtype, lag-time to cancer diagnosis, age at pregnancy or age at diagnosis.CONCLUSIONS: There was no association between IGF-1 and maternal breast cancer risk during early pregnancy in this large nested case-control study.Impact:Serum IGF-1 concentrations during early pregnancy may not be related to maternal risk of breast cancer.

Utilidad de la definición de Neumonía asociada a los cuidados sanitarios, los Criterios de Shorr y los Criterios de Aliberti, para predecir la presencia de gérmenes resistentes en la neumonía extrahopsitalaria en nuestro medio.

Es tracta d'un estudi prospectiu observacional de pacients atesos durant un any a Urgències per pneumònia. L'objectiu és valorar la utilitat de la definició de pneumònia associada a cures sanitàries (NACS), els criteris de Shorr i Aliberti per predir la presència de gèrmens resistents a la pneumònia extrahospitalària en el nostre medi. Concloent que la definició de NACS i la saturació d'oxigen són útils per predir el risc de pneumònia extrahospitalària per germen resistent. L'índex de Shorr i el de Aliberti no mostren utilitat en la predicció del risc de pneumònia per germen resistent al nostre medi.

European cancer mortality predictions for the year 2011.

Background: Mortality figures become available after some years.Materials and methods: Using the World Health Organization mortality and population data, we estimated numbers of deaths in 2011 from all cancers and selected sites for the European Union (EU) and six major countries, by fitting a joinpoint model to 5-year age-specific numbers of deaths. Age-standardized rates were computed using EUROSTAT population estimates.Results: The predicted number of cancer deaths in the EU in 2011 was 1 281 436, with standardized rates of 143/100 000 men and 85/100 000 women. Poland had the highest rates, with smaller falls over recent periods. Declines in mortality for major sites including stomach, colorectum, breast, uterus, prostate and leukemias, plus male lung cancer, will continue until 2011, and a trend reversal or a leveling off is predicted where upward trends were previously observed. Female lung cancer rates are increasing in all major EU countries except the UK, where it is the first cause of cancer death, as now in Poland. The increasing pancreatic cancer trends in women observed up to 2004 have likely leveled off.Conclusions: Despite falls in rates, absolute numbers of cancer deaths are stable in Europe. The gap between Western and former nonmarket economy countries will likely persist.

Trabajo interdisciplinar en la unidad terápeutica educativa del centro penitenciario de Villabona (Asturias)

En esta comunicación presentamos, a partir de una investigación que está realizando el Grupo de Acción Social Comunitaria (ASOC), de la Facultad de Educación Social y Trabajo Social Pere Tarrés- Universidad Ramon Llull, el modelo de trabajo comunitario que se está llevando a cabo en la Unidad Terapéutica Educativa (UTE) del Centro penitenciario de Villabona (Asturias). Unos de los fundamentos de la intervención desarrollada en la UTE y que es, a su vez, un criterio de calidad de la intervención social es el trabajo interdisciplinar. El eje central de este modelo de trabajo es un equipo con profesionales provenientes de diferentes disciplinas integrado por los trabajadores de los distintos ámbitos de la institución. Desde los educadores, a los psicólogos, pasando por el equipo de vigilancia, el cual desempeña funciones de tutoría con los internos, aspecto que comporta el cambio de rol de vigilante a educador. La innovación de este modelo proviene del hecho de que el equipo se define como un órgano de decisión y seguimiento transversal del modelo de intervención, aportando un destacado valor el papel activo y de trabajo en red que desempeñan, para la reinserción de los internos, las entidades sociales que participan dentro y fuera del centro penitenciario.

Motivo de consulta más frecuente del paciente oncológico hospitalizado en el Consorcio Hospital Provincial de Castellón. Estudio descriptivo.

Estudio descriptivo de los principales motivos de ingreso y síntomas más frecuentes del paciente oncológico. Se obtienen datos demográficos, clínicos y patológicos del paciente; así como el principal motivo de ingreso y la sintomatología que asocia. Resultados: El principal motivo de ingreso han sido las complicaciones derivadas de la neoplasia (56%), siendo el dolor mal controlado la principal causa. La sintomatología más prevalente ha sido la sequedad bucal (63%), dolor (60%) y la anorexia (55%). El dolor fue considerado el síntoma principal, sin embargo, el 63% de los pacientes que presentaban dolor, estaba mal o muy mal controlado (EVA>4).

Motivo de consulta más frecuente del paciente oncológico hospitalizado en el Hospital de Sagunto. Estudio descriptivo.

Estudi descriptiu dels principals motius d´ingrés i símptomes més freqüents del pacient oncològic. S´obtenen dades demogràfiques, clíniques i patològiques del pacient; així com el principal motiu d´ingrés i la simptomatologia que associa. Resultats: El principal motiu d´ingrés han estat les complicacions derivades de la neoplàsia (84 %), sent el dolor mal controlat la principal causa. La simptomatologia més prevalent ha estat l´anorèxia (69 %), dolor (60 %) i la perduda de pes (40 %). El dolor va ser considerat el símptoma principal, no obstant això, el 60 % dels pacients que presentaven dolor, estava mal o molt mal controlat (EVA>4).

Puesta en marcha y validación de un instrumento de preparación de muestras analíticas

El projecte que es presenta, és una posada a punt d’ equip i mètode analític,d’un preparador de mostres automàtic, en una empresa farmacèutica.Es tracta d’un equip automatitzat capaç de realitzar tot el proces de preparacióde mostres, per al seu anàlisi quantitatiu.L’objetiu, es realizar la posada a punt de l’equip, crear el procediment de treball,a partir del manual d’ús, elaborar el mètode d’anàlisi per a la quantificació delprincipi actiu en una especialitat farmacèutica i la posterior validació del mateix.Es presenta un resum de las consideracions generals, per a la confecció delprotocol de validació de mètodes analítics, utilitzats en la determinacióquantitativa de fàrmacs.Es descriu detalladament el proces de validació que inclou entre d’altres, ladeterminació dels paràmetres de linealitat, precisió, exactitut, etc, així com lapresentació dels resultats en l’informe final.Es realitza una comparació de resultats entre el mètode rutinari de preparació iel mètode automatitzat, amb sis lots de l’especialitat farmacèutica estudiada.Per acabar, es valora la millora que l’adquisició de l’equip suposa per allaboratori.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

PURPOSE Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy of inotuzumab ozogamicin in an expanded MTD cohort of patients with relapsed or refractory CD22(+) B-cell non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Inotuzumab ozogamicin was administered intravenously as a single agent once every 3 or 4 weeks at doses ranging from 0.4 to 2.4 mg/m(2). Outcomes included MTD, safety, pharmacokinetics, response, progression-free survival (PFS), and overall survival. Results Seventy-nine patients were enrolled. The MTD was determined to be 1.8 mg/m(2). Common adverse events at the MTD were thrombocytopenia (90%), asthenia (67%), and nausea and neutropenia (51% each). The objective response rate at the end of treatment was 39% for the 79 enrolled patients, 68% for all patients with follicular NHL treated at the MTD, and 15% for all patients with diffuse large B-cell lymphoma treated at the MTD. Median PFS was 317 days (approximately 10.4 months) and 49 days for patients with follicular NHL and diffuse large B-cell lymphoma, respectively. CONCLUSION Inotuzumab ozogamicin has demonstrated efficacy against CD22(+) B-cell NHL, with reversible thrombocytopenia as the main toxicity.